Skip to main content

Table 4 Univariate Cox regression analysis of association of various clinical factors with overall survival in melanoma patients with brain metastasis

From: Survival and clinical outcomes of patients with melanoma brain metastasis in the era of checkpoint inhibitors and targeted therapies

Variable Chi-squared Hazard ratio P value
Gender (male) 4.03 1.85 0.045*
Age 0.826 1.01 0.36
TIL level 2.23 0.628 0.135
Number of positive regional lymph nodes 3.13 1.05 0.077
Characteristics of brain metastasis
 Cerebellar metastases 6.43 2.19 0.011*
 Midbrain/pons metastasis 3.24 2.09 0.072
 Leptomeningeal disease 0.04 1.07 0.846
 Other site metastasis 0.03 0.92 0.867
 Size of largest brain metastases 0.816 1.01 0.367
 Number of brain metastases 18.8 1.19 < 0.00005*
 Presence of neurological symptoms 1.55 2.51 0.214
 Required steroid for brain metastasis 1.55 2.51 0.214
Extracranial Metastasis
 Presence of extracranial metastasis 2.29 1.49 0.13
 Presence of liver metastasis 2.25 1.94 0.134
 Presence of lung metastasis 0.527 1.30 0.468
 Presence of bone metastasis 0.06 1.09 0.813
 Presence of adrenal metastasis 5.39 4.50 0.02*
Therapy
 Craniotomy 10.0 0.418 0.0015*
 Stereotactic radiosurgery 7.72 0.434 0.0055*
 Whole brain radiation therapy 16.2 3.85 0.0001*
 Number of prior systemic therapies 0.613 1.09 0.434
 Anti-CTLA4 antibody after BM 0.658 0.79 0.417
 Anti-PD-1 antibody after BM 10.0 0.376 0.0016*
 BRAF inhibitor after BM 0.05 1.07 0.82
  1. BM, initial diagnosis of brain metastasis;
  2. *p-value is < 0.05